TopoTarget's Savene® Recommended Treatment for Anthracycline Extravasation by European Oncology Nursing Society

TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen Ø
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771

www.topotarget.com
TopoTarget's Savene® Recommended Treatment for Anthracycline Extravasation by
European Oncology Nursing Society 

Copenhagen, Denmark - January 14, 2008- TopoTarget A/S (OMX:  TOPO) today
announced that Savene® has been recommended as standard treatment for
anthracycline extravasation in the new European Oncology Nursing society (EONS)
guidelines. 
The guidelines offer a practical guide to extravasation management from
prevention and recognition through to management strategies and advice on the
implementation of guidelines into clinical practice. 
The guidelines are based on existing literature and form a web-based toolkit
available to oncology nurses. 
The guidelines state that due to the high level of evidence that exists for
Savene® this specific antidote is changing the way antidotes are recommended: 
“In the past few years, new data from preclinical and clinical studies has
changed the way antidotes are used in anthracycline extravasation, particularly
that for Savene®. And, it has since become the only licensed specific antidote
to anthracycline extravasation. As a result, more recent guidance in this area
recommends the use of Savene® in the treatment of anthracycline extravasation
from both a central- and a peripheral line.” 
Savene® was launched on the European market in 2006 and the product was
launched in the US in October 2007 under the name Totect™. In both markets it
is the only approved therapy for anthracycline extravasations. 
 “I am very pleased Savene® is included in EONS guidelines.  We believe this
strong recommendation should result in hospitals that administer anthracyclines
deciding to stock Savene® ready for use in case an anthracycline extravasation
occurs.” Said Dr. Peter Buhl Jensen, CEO of TopoTarget. “The new guidelines
show that European oncology nurses, who are key players in the administration
of chemotherapy in most of the European countries, recognise the importance for
cancer patients of having a successful treatment on hand for this terrible
accident.” 
The guidelines will be officially launched at a satellite symposium during the
EONS Spring Convention in Geneva on March 28, 2008 and are currently available
for download from the EONS website. 
http://www.cancerworld.org/CancerWorld/moduleStaticPage.aspx?id=3891&id_sito=2&i
d_stato=1 

Today's news does not change TopoTarget's full-year financial guidance for 2007.

TopoTarget A/S

	
For further information, please contact:

Ulla Hald Buhl 	Telephone	+45 39 17 83 92
Director IR & Communications	Mobile	+45 21 70 10 49


Background information

About Totect™/Savene® 
Savene®/Totect™  is a catalytic inhibitor of Topoisomerase II, an enzyme found
in the cell nucleus. Topoisomerase enzymes are essential for cell growth and
proliferation and the target for a group of anti-cancer chemotherapeutics
called anthracyclines. Savene®/Totect™ blocks the activity of the topoisomerase
enzyme and prevents the effect of anthracyclines. 
Savene®/Totect™ is used as a detoxifying agent, administered intravenously as
an antidote following an extravasation. An extravasation is a serious clinical
accident in which anthracyclines accidentally leak into surrounding tissue. The
high concentration of drug causes severe and cumulative damage to the skin,
subcutaneous tissue, muscle and nerves. Current treatment often involves
surgical removal of the tissue followed by plastic surgery and rehabilitation.
The use of dexrazoxane (the active ingredient in Totect™/Savene®) to treat
anthracycline extravasation is protected by patent in several countries
including EU and the US. The US patent number is 6,727,253 B2. 

About EONS
The European Oncology Nursing Society (EONS) is dedicated to developing,
enhancing and promoting cancer nursing in Europe through educational, research,
and practice based initiatives. EONS is mainly focussed on meeting the needs of
nurses who routinely provide care for patients with cancer. 
EONS is comprised of individual cancer nurses, national oncology nursing
societies and institutions involved in cancer care which in turn represent
approximately 22000 nurses in 30 European countries.  EONS has contacts with
other societies, like ONS, ISNCC, MASCC, FECS, ESO and PCN. 

About TopoTarget
TopoTarget (OMX: TOPO) is a biotech company, headquartered in Denmark and with
subsidiaries in the US, Switzerland, Germany and the UK, dedicated to finding
''Answers for Cancer'' and developing improved cancer therapies. TopoTarget is
founded and run by clinical cancer specialists and combines years of hands-on
clinical experience with in-depth understanding of the molecular mechanisms of
cancer. Focus lies on highly predictive cancer models and key cancer targets
(including HDACi, NAD+, mTOR, FasLigand and topoisomerase II inhibitors) and a
strong development foundation has been built. TopoTarget has a broad portfolio
of small molecule pre-clinical drug candidates and nine drugs (both small
molecules and protein based) are in clinical development, including both novel
anti-cancer therapeutics and new cancer indications for existing drugs.
Savene®/Totect™ were approved by EMEA in 2006 and the FDA in 2007 and is
TopoTarget's first product on the market. For more information, please refer to
www.topotarget.com. 

TopoTarget Safe Harbour Statement
This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements.  TopoTarget cautions investors
that there can be no assurance that actual results or business conditions will
not differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: The risk that any one or more of the drug development programs of
TopoTarget will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrolment issues or based on new information from
non-clinical or clinical studies or from other sources; the success of
competing products and technologies; technological uncertainty and product
development risks;  uncertainty of additional funding; TopoTarget's history of
incurring losses and the uncertainty of achieving profitability; TopoTarget's
stage of development as a biopharmaceutical company; government regulation;
patent infringement claims against TopoTarget's products, processes and
technologies; the ability to protect TopoTarget's patents and proprietary
rights; uncertainties relating to commercialization rights; and product
liability expo-sure; We disclaim any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise, unless required by